Literature DB >> 11015339

Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group.

J J Kastelein1, J W Jukema, A H Zwinderman, S Clee, A J van Boven, H Jansen, T J Rabelink, R J Peters, K I Lie, G Liu, A V Bruschke, M R Hayden.   

Abstract

BACKGROUND: Raised triglyceride-rich lipoproteins significantly increase the risk for cardiovascular disease. Variation in the activity of the enzyme lipoprotein lipase (LPL), which is crucial in the removal of these lipoproteins, may therefore modulate this risk. METHODS AND
RESULTS: Postheparin levels of LPL activity and mass were measured in a large cohort of male coronary artery disease patients participating in the Regression Growth Evaluation Statin Study (REGRESS), a lipid-lowering regression trial. In addition, the relationships between LPL activity and mass and severity of angina pectoris according to the NYHA classification and silent ischemia on 24-hour ambulatory ECG monitoring were assessed. Patients in different LPL activity quartiles and mass had different severities of angina; a total of 47% of patients in the lowest LPL quartile reported class III or IV angina. In contrast, only 29% in the highest activity quartile (P:=0.002) had severe angina. These parameters were supported by ambulatory ECG results, for which the total ischemic burden in the lowest LPL activity quartile was 36. 5+/-104.1 mm x min compared with 14.8+/-38.8 mm x min in the highest quartile of LPL activity (P:=0.001). LPL activity levels were strongly correlated with LPL mass (r=0.70, P:<0.0001). A significant association between the LPL protein mass and NYHA class (P:=0.012) was also demonstrated.
CONCLUSIONS: We have demonstrated a significant relationship between LPL mass and activity and severity of ischemia as defined by angina class and ambulatory ECG. These results suggest that LPL influences risk for coronary artery disease by both catalytic and noncatalytic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015339     DOI: 10.1161/01.cir.102.14.1629

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.

Authors:  Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2017-06-13       Impact factor: 4.766

Review 3.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

4.  The association of lipoprotein lipase PvuII polymorphism and niacin intake in the prevalence of metabolic syndrome: a KMSRI-Seoul study.

Authors:  Eunjung Shin; Na-Young Park; Yangsoo Jang; Hyunhee Oh; Jayoung Jeong; Yunsook Lim; Myoungsook Lee
Journal:  Genes Nutr       Date:  2011-10-29       Impact factor: 5.523

5.  Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects.

Authors:  Remco Franssen; Stephen G Young; Frank Peelman; Jozef Hertecant; Jeroen A Sierts; Alinda W M Schimmel; André Bensadoun; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Anne P Beigneux
Journal:  Circ Cardiovasc Genet       Date:  2010-02-02

6.  Increased postprandial triglyceride-rich lipoprotein levels in elderly survivors of myocardial infarction.

Authors:  Samira Lekhal; Trond Børvik; Arne Nordøy; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-04-04       Impact factor: 1.880

7.  Molecular genetics of myocardial infarction.

Authors:  Yoshiji Yamada; Sahoko Ichihara; Tamotsu Nishida
Journal:  Genomic Med       Date:  2008-08-14

8.  Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease.

Authors:  Martin Javorský; Daniela Gasperíková; Jozef Ukropec; Barbora Sedláková; Igor Riecanský; Ol'ga Krizanová; Elena Seböková; Martina Dobríková; Iwar Klimes; Ivan Tkác
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.

Authors:  Anne P Beigneux; Remco Franssen; André Bensadoun; Peter Gin; Kristan Melford; Jorge Peter; Rosemary L Walzem; Michael M Weinstein; Brandon S J Davies; Jan A Kuivenhoven; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Stephen G Young
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-19       Impact factor: 8.311

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.